Patents by Inventor Michael P. Smolinski

Michael P. Smolinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116904
    Abstract: HM30181 (shown below) can be used to improve absorption of cancer chemotherapy drugs, such as paclitaxel. Herein are described various polymorphisms of HM30181, in particular polymorphisms B, D, E, F, G, H, I, J, K, L, and M as well as their physical properties and methods for their preparation and characterization.
    Type: Application
    Filed: April 19, 2023
    Publication date: April 11, 2024
    Inventors: Sameer URGAONKAR, Michael P. SMOLINSKI, Johnson Yiu-Nam LAU
  • Patent number: 11739079
    Abstract: HM30181 (shown below) can be used to improve absorption of cancer chemotherapy drugs, such as paclitaxel. Herein are described various polymorphisms of HM30181, in particular polymorphism C, as well as their physical properties and methods for their preparation and characterization.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: August 29, 2023
    Assignee: ATHENEX R&D. LLC
    Inventors: Sameer Urgaonkar, Michael P. Smolinski, Johnson Yiu-Nam Lau
  • Patent number: 11739089
    Abstract: The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: August 29, 2023
    Assignee: Athenex, Inc.
    Inventors: Sameer Urgaonkar, Ahmed M. Said, Nader N. Nasief Abdel Sayed, Laura Beth Pitzonka, Murray John Cutler, Michael P. Smolinski, Johnson Yiu-Nam Lau
  • Publication number: 20230181566
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.
    Type: Application
    Filed: October 11, 2022
    Publication date: June 15, 2023
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, Wing Kai CHAN, Michael P. SMOLINSKI
  • Publication number: 20230076079
    Abstract: Polymorphs of HM30181, their physical properties, and methods for their preparation are described.
    Type: Application
    Filed: October 28, 2021
    Publication date: March 9, 2023
    Inventors: Sameer URGAONKAR, Michael P. SMOLINSKI, Johnson Yiu-Nam LAU
  • Publication number: 20220106301
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which expression of P-glycoprotein and/or cytochrome P450 (e.g., CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).
    Type: Application
    Filed: October 7, 2021
    Publication date: April 7, 2022
    Inventors: Sameer URGAONKAR, Ahmed M. SAID, Nader N. NASIEF ABDEL SAYED, Laura Beth PITZONKA, Murray John CUTLER, Michael P. SMOLINSKI, Johnson Yiu-Nam LAU
  • Publication number: 20220106312
    Abstract: The present disclosure relates to compounds of Formula (IA) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which P-glycoprotein and/or cytochrome P450 (e.g. CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).
    Type: Application
    Filed: October 7, 2021
    Publication date: April 7, 2022
    Inventors: Sameer URGAONKAR, Ahmed M. SAID, Nader N. NASIEF ABDEL SAYED, Laura Beth PITZONKA, Murray John CUTLER, Michael P. SMOLINSKI, Johnson Yiu-Nam LAU
  • Publication number: 20220098152
    Abstract: The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using the same for the treatment of a cell proliferative disorder in which a tyrosine kinase plays a role.
    Type: Application
    Filed: December 9, 2021
    Publication date: March 31, 2022
    Inventor: Michael P. SMOLINSKI
  • Patent number: 11230527
    Abstract: The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using the same for the treatment of a cell proliferative disorder in which a tyrosine kinase plays a role.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: January 25, 2022
    Assignee: Athenex HK Innovative Limited
    Inventor: Michael P. Smolinski
  • Publication number: 20210347763
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Application
    Filed: December 8, 2020
    Publication date: November 11, 2021
    Inventors: Michael P. SMOLINSKI, Sameer URGAONKAR, James Lindsay CLEMENTS, David G. HANGAUER, JR.
  • Publication number: 20210196724
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 1, 2021
    Inventors: Michael P. SMOLINSKI, Nader N. NASIEF ABDEL SAYED, David G. HANGAUER, JR.
  • Patent number: 10973828
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 13, 2021
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.
  • Patent number: 10899747
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: January 26, 2021
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
  • Publication number: 20200255380
    Abstract: The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventor: Michael P. SMOLINSKI
  • Patent number: 10669236
    Abstract: The present application provides solid Forms A, B, and C of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same. The compounds disclosed herein may be used in the treatment or prevention of a disease or condition in which a tyrosine kinase plays a role.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 2, 2020
    Assignee: Athenex HK Innovative Limited
    Inventor: Michael P. Smolinski
  • Publication number: 20200071305
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 5, 2020
    Inventors: Michael P. SMOLINSKI, Sameer URGAONKAR, James Lindsay CLEMENTS, David G. HANGAUER, JR.
  • Patent number: 10450303
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
  • Publication number: 20190314361
    Abstract: The application pertains to pharmaceutical combinations of orally administered paclitaxel and a P-gp inhibitor. The pharmaceutical combinations are suitable for the treatment of an angiosarcoma in a subject and for reducing or preventing toxicity, hypersensitivity-type infusion reactions, and other negative outcomes resulting from or associated with intravenously administered paclitaxel (e.g., Taxol® or paclitaxel formulated with Cremophor®) therapy in a subject suffering from an angiosarcoma.
    Type: Application
    Filed: April 12, 2019
    Publication date: October 17, 2019
    Inventors: Min-Fun Rudolf KWAN, Johnson Yiu-Nam LAU, Wing Kai CHAN, Michael P. SMOLINSKI
  • Publication number: 20190125754
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 2, 2019
    Inventors: Michael P. SMOLINSKI, Nader N. NASIEF ABDEL-SAYED, David G. HANGAUER, JR.
  • Publication number: 20190071402
    Abstract: The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide, and methods of preparing and using same.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 7, 2019
    Inventor: Michael P. SMOLINSKI